Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”)
Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that the U.S. Food and Drug Administration (FDA) has accepted an investigational new drug (IND) application for the company’s lead product candidate, TGN-S11, for the treatment of HPV-induced cancers.
“The acceptance of the TGN-S11 IND is an important milestone for Toragen, as we work toward a treatment for HPV-induced cancers,” said Sandra Coufal, MD, Toragen’s CEO. “We are now turning our focus to clinical execution with the commencement of our Phase 1 clinical trial and look forward to beginning to dose patients by mid-2023.”
The Phase 1 clinical trial is a dose escalation trial as well as a dose expansion trial in combination with a checkpoint inhibitor for patients with HPV-induced cancers.
